News for Y-mAbs Therapeutics, Inc. (YMAB)

On March 31, 2025, Caligan Partners LP (Trades, Portfolio), a New York-based investment firm, expanded its position in Y-mAbs Therapeutics Inc by acquiring an a

Stock futures are mixed, signaling a potential pause following Monday’s rally driven by optimism over a temporary U.S.-China trade deal. In corporate news, UnitedHealth Group shares plunged 10% after CEO Andrew Witty stepped down, with former CEO Stephen Hemsley stepping in. The company also suspended its outlook due to rising medical costs. Bitcoin has regained value above $103,800, aligning with Coinbase’s rise after inclusion into the S&P 500. In pre-market trading, S&P 500 futures were fla

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Vice President, Head of...

Y-mAbs Therapeutics Inc (YMAB) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $19.61 million, and the ear

Y-mAbs Therapeutics (YMAB) recently shared that the National Comprehensive Cancer Network (NCCN) has endorsed naxitamab-gqgk. This approval is part of the NCCN

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical

PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical

Y-mAbs Therapeutics (YMAB) will announce its Q1 2025 financial results on May 13, 2025, before the market opens. The company will host a conference call

YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-mAbs Therapeutics (YMAB) recently presented groundbreaking preclinical and translational pharmacokinetic data concerning their CD38-SADA compound at the 2025

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the ”œCompany” or ”œY-mAbs”) ( YMAB), a commercial-stage biopharmaceutical compa

Y-mAbs Therapeutics, under the ticker YMAB, has initiated a significant Phase 1 clinical trial targeting relapsed or refractory non-Hodgkin Lymphoma. The first

New York-based Y-mAbs Therapeutics, Inc. (YMAB) is down over 26 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Total Revenue: $87.7 million for the full year 2024.DANYELZA Net Product Revenues: $85.2 million for the full year 2024; $24.5 million for Q4 2024, a 5% increa

Mar 04, 2025 / 01:00PM GMTOperator Good morning and welcome to Y-mAbs Therapeutics Inc's earnings conference call for the fourth quarter in full year 2024. (Ope

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Head-IRMichael Rossi -...

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -15.38% and 0.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $26.5 million for Q4 2024, slightly below the estimated $27.29 million, but marking a 13% increase year-over-year.Annual Revenue: $87.7 million for 20